Ineeyan Vivekanandan Ariyaratnam

Ineeyan Vivekanandan Ariyaratnam

Active Director Managing Director DIN 03596235
DIN 03596235 First appointment Aug 2011 Primary industry Chemicals and Materials
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 1 historical roles
Total affiliations 4 Since Aug 2011
Shareholding value •••• Premium profile

About Ineeyan Vivekanandan Ariyaratnam

Data last updated:

Ineeyan Vivekanandan Ariyaratnam is a Managing Director at Harris & Menuk Chemicals Private Limited (since 2015), Director at Epygen Biotech Private Limited (since 2011) and Director at Genores Biotech Private Limited (since 2019). The companies operate in Chemicals and Materials. The 3 current companies with reported revenue have a combined latest revenue of ₹78.57 Cr; the largest is Harris & Menuk Chemicals Private Limited at ₹54.94 Cr (FY 2025). Earlier, Ineeyan Vivekanandan Ariyaratnam was a Director at Beva Silicones Private Limited (from 2011).

DIN 03596235
Primary Designation Managing Director
Industry Chemicals and Materials
First Appointment 25 Aug 2011
Oldest Company Age 17 yrs
Largest company Harris & Menuk Chemicals Private Limited · ₹54.94 Cr (FY 2025)
Combined revenue ₹78.57 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Managing Director03 Mar 20152015₹54.94 Cr (FY 2025)Active
Epygen Biotech Private Limited U24233MH2011PTC221254
Director25 Aug 20112011₹23.61 Cr (FY 2025)Active
Genores Biotech Private Limited U74999MH2018PTC307155
Director26 Mar 20192018₹1.7 Lakh (FY 2024)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Beva Silicones Private Limited U24299TN2008PTC070032
Director03 Oct 20112008₹28.49 Cr (FY 2024)Amalgamated

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Harris & Menuk Chemicals Private Limited
Epygen Biotech Private Limited
Beva Silicones Private Limited
Genores Biotech Private Limited
Premium access

Shareholding and investment profile for Ineeyan Vivekanandan Ariyaratnam

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ineeyan Vivekanandan Ariyaratnam

Ineeyan Vivekanandan Ariyaratnam currently holds 3 directorships: Harris & Menuk Chemicals Private Limited (Managing Director, since 03 Mar 2015, revenue ₹54.94 Cr (FY 2025)); Epygen Biotech Private Limited (Director, since 25 Aug 2011, revenue ₹23.61 Cr (FY 2025)); Genores Biotech Private Limited (Director, since 26 Mar 2019, revenue ₹1.7 Lakh (FY 2024)).

Ineeyan Vivekanandan Ariyaratnam was first appointed on 25 Aug 2011 as Director at Epygen Biotech Private Limited. The most recent appointment on record is 26 Mar 2019 at Genores Biotech Private Limited.

The 3 current companies of Ineeyan Vivekanandan Ariyaratnam that report revenue have a combined latest revenue of ₹78.57 Cr: Harris & Menuk Chemicals Private Limited ₹54.94 Cr (FY 2025); Epygen Biotech Private Limited ₹23.61 Cr (FY 2025); Genores Biotech Private Limited ₹1.7 Lakh (FY 2024).

Ineeyan Vivekanandan Ariyaratnam held 1 earlier board appointment: Beva Silicones Private Limited (Director, from 03 Oct 2011).

The current boards of Ineeyan Vivekanandan Ariyaratnam's companies include Tuticorin Subbiah Srinivasan (Harris & Menuk Chemicals Private Limited), Venkatakrishnan Santharaman (Harris & Menuk Chemicals Private Limited), Debayan Sukhamoy Ghosh (Epygen Biotech Private Limited), Manickam (Epygen Biotech Private Limited), Soumitro Deb (Epygen Biotech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available